Indications for: WEGOVY
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30kg/m2 (obese) or ≥27kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia).
Limitations of Use:
Do not use with other semaglutide-containing products or with any other GLP-1 receptor agonist. Safety and efficacy have not been established with other products intended for weight loss, including prescription drugs, OTC drugs, and herbal preparations. Not studied in those with a history of pancreatitis.
Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Escalate dose with the following schedule (to minimize risk of GI effects): Weeks 1–4: 0.25mg once weekly; Weeks 5–8: 0.5mg once weekly; Weeks 9–12: 1mg once weekly; Week 13–16: 1.7mg once weekly; Week 17 and onward: 2.4mg once weekly. Consider delaying dose escalation for 4 weeks if increased dose not tolerated. If the maintenance 2.4mg once-weekly dose is not tolerated, may temporarily decreased to 1.7mg once weekly for max 4 weeks. After 4 weeks, increase to the 2.4mg once weekly; discontinue if 2.4mg dose is not tolerated.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors.
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Monitor for acute pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis. Acute gallbladder disease. Monitor renal function when initiating or escalating doses, or in renal impairment. History of diabetic retinopathy; monitor for progression. History of suicidal attempts or ideation: avoid. Monitor for emergence or worsening depression, suicidal thoughts or behavior; discontinue if occurs. Monitor blood glucose prior to and during treatment in those with T2DM. Monitor heart rate periodically; discontinue if sustained increases. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Discontinue if hypersensitivity reactions occur. Pregnancy. Females of reproductive potential: discontinue ≥2 months prior to planned pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need a lower dose of these. May affect absorption of other oral drugs (delayed gastric emptying); caution.
Nausea, diarrhea, vomiting, constipation, abdominal pain/distension, headache, fatigue, dyspepsia, dizziness, eructation, hypoglycemia in T2DM, flatulence, gastroenteritis, GERD; acute kidney injury, retinal disorders, lab abnormalities (eg, increased lipase or amylase), hypersensitivity reactions.
Generic Drug Availability:
Single-dose prefilled pens—4